Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River ...

Charles River Laboratories International Inc CRL reported Q1 sales of $1.03 billion, an increase of 12.6% Y/Y, beating the consensus of $986.35 million. The company reported adjusted EPS of $2.78, ...

First quarter results continued to suffer for Charles River (CRL). Adjusted EPS was $2.27, down 18% from a year ago. Revenue dropped 3.3% on an organic basis.While EPS beat estimates by 21c, operating ...

Charles River Laboratories (CRL) reported $1.06 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 8.9%. EPS of $2.69 for the same period compares to $2.77 a ...

Get the latest news on Charles River stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Charles River performance ...